Related Experiment Video
Updated: Jul 10, 2025
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Bad Liver and a Broken Heart: Hepatitis B in the Newborn
Insights
Hepatitis B vaccination and immune globulin therapy protect newborns from infection. Healthcare providers should follow guidelines to prevent chronic hepatitis B and its complications.
Area of Science:
- * Hepatology and Immunology
- * Vaccinology and Neonatal Care
Background:
- * Hepatitis B virus (HBV) infection is a major global health concern, causing significant morbidity and mortality.
- * Neonates are particularly vulnerable to HBV due to immature immune systems, with perinatal exposure posing the highest risk for chronic infection, cirrhosis, and hepatocellular carcinoma.
- * The United States has seen a substantial decrease in acute HBV infections following widespread recombinant vaccine adoption.
Purpose of the Study:
- * To review the critical role of hepatitis B vaccination and immune globulin therapy in protecting neonates.
- * To emphasize the importance of screening pregnant women for HBV infection.
- * To guide healthcare providers on optimal management strategies for HBV prevention in newborns.
Main Methods:
- * Review of current national guidelines and scientific literature on hepatitis B prevention in neonates.
- * Analysis of the risks associated with vertical and horizontal HBV transmission.
- * Evaluation of the efficacy of recombinant vaccines and hepatitis B immune globulin (HBIG).
Main Results:
- * Recombinant vaccines provide partial protection to neonates immediately after birth.
- * Hepatitis B immune globulin administration is effective in preventing infection after suspected or confirmed exposure.
- * Delayed vaccination is recommended for low-birth-weight neonates due to immune system immaturity.
Conclusions:
- * Screening pregnant women for hepatitis B surface antigen and viral load is crucial for identifying at-risk infants.
- * Adherence to national guidelines for hepatitis B vaccination and HBIG is essential for healthcare providers.
- * Informed decision-making, supported by provider education, can lead to the eradication of this vaccine-preventable disease.
Abstract:
Hepatitis B viral infection is a significant source of morbidity and mortality worldwide. The United States has experienced a precipitous drop in acute hepatitis B infection after the introduction and widespread adoption of recombinant vaccines. Neonates experience significant risk from both vertical and horizontal hepatitis B exposure during a period of immaturity of the innate and adaptive immune systems. Acquisition of hepatitis B virus at or near birth confers the highest lifetime risk of chronic infection and subsequent complications including liver cirrhosis and hepatocellular carcinoma. Pregnant women should be screened for the presence of hepatitis B surface antigen, indicating acute or chronic infection, and, if positive, hepatitis B viral deoxyribonucleic acid, allowing for quantification of viral load. The development of highly effective and safe recombinant vaccines allows partial protection of late preterm and term neonates immediately after birth. Additionally, administration of hepatitis B immune globulin in the setting of suspected or confirmed exposure supplements the immune response and decreases the risk of chronic infection. The optimal timing of vaccination is later in low-birth-weight neonates due to the aforementioned immune system immaturity. Health care providers serving neonates must familiarize themselves with national guidelines regarding hepatitis B vaccination and hepatitis B immune globulin therapy. Understanding the risks of infection and the evidence basis supporting vaccination and immunotherapy will allow providers to educate families and support decision-making, with the potential to eradicate this vaccine-preventable illness in our lifetime.
Related Concept Videos
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:19Rh Blood Group
01:26Sexually Transmitted Infections